AstraZeneca's trial failure dents credibility more than valuation, shares drop 9%.

AstraZeneca's drug Wainua failed a key trial, causing its shares to fall 9%, the largest drop in the FTSE 100 that day. Jefferies notes the impact on the stock price exceeds the drug's actual valuation contribution, which is about 2% of net present value. The failure raises concerns about management's trial design, especially due to a high increase in patients on a competing drug during the study. Despite this, patients on Wainua alone showed a significant 29% reduction in events. The setback does not threaten AstraZeneca's long-term $80 billion sales target for 2030, but investor confidence may remain low until upcoming trial results in lung cancer are released.